Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk ...

The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...

Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...

BARCELONA, Spain — New phase 3 findings revealed that most patients with newly diagnosed high-risk endometrial cancer did not benefit from receiving adjuvant immunotherapy alongside chemotherapy ...

Pembrolizumab plus chemoradiotherapy improved survival in patients with previously untreated, high-risk locally advanced ...